Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer.
10.3349/ymj.2016.57.5.1124
- Author:
Do Chang MOON
1
;
Hee Seung LEE
;
Yong Il LEE
;
Moon Jae CHUNG
;
Jeong Youp PARK
;
Seung Woo PARK
;
Si Young SONG
;
Jae Bock CHUNG
;
Seungmin BANG
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine and Yonsei Institute of Gastroenterology, Seoul, Korea. bang7028@yuhs.ac
- Publication Type:Original Article
- Keywords:
Hydroxymethylglutaryl-CoA reductase inhibitors;
pancreatic neoplasms;
erlotinib;
gemcitabine
- MeSH:
Adenocarcinoma/*drug therapy/secondary;
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Deoxycytidine/administration & dosage/analogs & derivatives;
Disease-Free Survival;
Erlotinib Hydrochloride/administration & dosage;
Female;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use;
Male;
Middle Aged;
Neoplasm Staging;
Pancreatic Neoplasms/*drug therapy/pathology;
Retrospective Studies;
Survival Rate;
Young Adult
- From:Yonsei Medical Journal
2016;57(5):1124-1130
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Erlotinib-gemcitabine combined chemotherapy is considered as the standard treatment for unresectable pancreatic cancer. This study aimed to determine the clinical factors associated with response to this treatment. MATERIALS AND METHODS: This retrospective study included 180 patients with unresectable pancreatic cancer who received ≥2 cycles of gemcitabine-erlotinib combination therapy as first-line palliative chemotherapy between 2006 and 2014. "Long-term response" was defined as tumor stabilization after >6 chemotherapy cycles. RESULTS: The median progression-free survival (PFS) and overall survival (OS) were 3.9 and 8.1 months, respectively. On univariate analysis, liver metastasis (p=0.023) was negatively correlated with long-term response. Locally advanced stage (p=0.017), a history of statin treatment (p=0.01), and carcinoembryonic antigen levels <4.5 (p=0.029) had a favorable effect on long-term response. On multivariate analysis, a history of statin treatment was the only independent favorable factor for long-term response (p=0.017). Prognostic factors for OS and PFS were significantly correlated with liver metastasis (p=0.031 and 0.013, respectively). A history of statin treatment was also significantly associated with OS after adjusting for all potential confounders (hazard ratio, 0.48; 95% confidence interval, 0.26-0.92; p=0.026). CONCLUSION: These results suggest that statins have a favorable effect on "long-term response" to gemcitabine-erlotinib chemotherapy in unresectable pancreatic cancer patients. Statins may have a chemoadjuvant role in stabilizing long-term tumor growth.
